The term COVID-19 testing refers to laboratory or point-of-care methods used to detect infection with the SARS‑CoV‑2 virus or to identify the immune response that follows infection. Tests fall into two broad categories: those that look for the virus itself (direct detection) and those that look for antibodies produced by the body after infection (serology). Their results inform clinical care, public-health decisions, and epidemiological estimates.

Types of tests

Molecular tests detect viral genetic material and are the standard for diagnosing an active infection. A common laboratory method is polymerase chain reaction (PCR), though other nucleic acid amplification tests exist. Some rapid tests also detect viral proteins (antigen tests) and can indicate current infectiousness more quickly but with different accuracy profiles. Separate from these, antibody or serology tests identify past exposure by measuring immune proteins in blood; see antibody testing.

How tests work and sample types

Molecular and antigen tests usually use respiratory specimens — nasal, nasopharyngeal, throat swabs, or saliva — to find the virus itself (detect active infection). Serology tests use blood or serum. Molecular assays amplify fragments of viral RNA so low levels can be detected, whereas antigen assays bind to viral proteins without amplification. Serology assays detect classes of immunoglobulins (IgM, IgG) that appear days to weeks after infection.

Accuracy, timing, and interpretation

No test is perfect. Sensitivity (ability to identify true positives) and specificity (ability to exclude false positives) vary by method, specimen quality, and timing relative to symptom onset. Molecular tests are most reliable early in infection; antibodies may not be detectable until later. False negatives can arise from poor sampling or testing too early, and false positives are possible with imperfect specificity. Interpreting results requires clinical context and knowledge of pretest probability.

Uses and public-health importance

Testing serves several roles: diagnosing symptomatic individuals, screening exposed or high-risk groups, guiding isolation and treatment, and providing data for surveillance. Aggregated test results are used to estimate disease severity metrics such as the infection fatality ratio and to assess population immunity levels, including studies of mortality rates and herd immunity. However, estimates depend on testing coverage, representativeness, and assay accuracy.

History, development, and limitations

During the early stages of the pandemic many regions faced shortages of tests, supplies, and lab capacity, limiting reliable national estimates. Over time, test technology and access improved, producing a range of laboratory and rapid point-of-care options. Despite advances, uncertainties remain about how long antibody-based protection lasts and how test results correlate with immunity and infectiousness. Continued evaluation of assays and careful interpretation of data are essential for effective use of testing in clinical care and public health.

Notable distinctions

  • Molecular vs antigen: molecular tests detect viral RNA (higher sensitivity); antigen tests detect proteins (faster, simpler).
  • Active vs past infection: viral tests indicate current infection; antibodies indicate previous exposure and potential immune response.
  • Population surveillance: representative testing and repeated surveys are needed to estimate true prevalence and to inform estimates of severity and immunity.

When using test results for personal or policy decisions, consider timing, test type, and local public-health guidance. Ongoing research continues to refine how best to deploy tests to control spread and protect populations.

More on viral detection | PCR methods | Antibody testing | Mortality estimates | Herd immunity concepts